drugset
drugset / Trial / NCT02920190

Antigen-Lipid-Driven Monoclonal Gammopathies Targeting Epicardial Fat

NCT02920190 ↗

Phase 4 Withdrawn University of Miami
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this research study is to learn about the effect of Liraglutide (Victoza) on the fat of the heart and some fat cells in blood.

Timeline

Start
2020-09-01
Primary completion
2021-09-01
Completion
2021-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Liraglutide Peptide 1.8 mg Subcutaneous

Indications

monoclonal gammopathy obesity disorder